A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. Patients with a previously unt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2012-11, Vol.23 (11), p.2834-2842
Hauptverfasser:	Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., Galimi, F., McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Aged, 80 and over AMG 479 Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences conatumumab Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Female ganitumab Gastroenterology. Liver. Pancreas. Abdomen Gemcitabine Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Neoplasm Metastasis - drug therapy pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pharmacology. Drug treatments phase 2 trial Placebos Receptor, IGF Type 1 - antagonists & inhibitors Receptor, IGF Type 1 - immunology Survival Rate Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!